Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + rituximab vs lenalidomide + rituximab or bortezomib + rituximab in relapsed/refractory mantle cell lymphoma
2022-000364-21Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Complete response rate (CR rate), Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and 1 more. Started Aug 2022; status: active.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-000364-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000364-21.